Cynosure Prepared for Growth After Recession, says CEO

In an exclusive video interview with, Cynosure (NASDAQ: CYNO) President and CEO Michael Davin discusses Cynosure’s expanding position in the global market as a provider of light-based medical treatments and the strategic shifts that allowed Cynosure to weather the last few years of worldwide economic recession. Even as competitors fell apart, says Davin, Cynosure continued to innovate: “We spent at the same level [on R&D] as we did during the high times […] we have $77 million in cash, no debt, and last year we acquired two companies and also acquired a distribution relationship.” He explains how the company made major cuts to operating expenses in 2009 and 2010, resulting in top-line revenue growth of 35% in 2011 – more than any other company in their industry, including public names like Syneron Medical (NASDAQ:  ELOS), Palomar Medical (NASDAQ: PMTI), Solta Medical (NASDAQ: SLTM) or Cutera (NASDAQ: CUTR).